Cody J. Peer, Ph.D.
Affiliations: | 2009 | West Virginia University, Morgantown, WV, United States |
Area:
PharmacyGoogle:
"Cody Peer"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Patrick S. Callery | grad student | 2009 | West Virginia University | |
| (Properties of a dehydroalanine analog of glutathione: A reactive electrophilic busulfan metabolite.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wei BR, Hoover SB, Peer CJ, et al. (2020) Efficacy, tolerability and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma. Molecular Cancer Therapeutics |
| Peer CJ, Goldstein DA, Goodell JC, et al. (2020) Opportunities for using In Silico-Based Extended Dosing Regimens for Monoclonal Antibody Immune Checkpoint Inhibitors. British Journal of Clinical Pharmacology |
| Elechalawar CK, Hossen MN, Shankarappa P, et al. (2020) Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. International Journal of Nanomedicine. 15: 991-1003 |
| Rodgers LT, Lester McCully CM, Odabas A, et al. (2020) Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemotherapy and Pharmacology |
| Pegna GJ, Ahmad MI, Yu Y, et al. (2020) Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. Journal of Clinical Oncology. 38: 3553-3553 |
| Wedekind MF, Del Rivero J, Arnaldez FI, et al. (2020) A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer. Journal of Clinical Oncology. 38: 11540-11540 |
| Alewine C, Ahmad M, Peer CJ, et al. (2019) Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Li M, Nguyen L, Subramaniyan B, et al. (2019) PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Conlon KC, Potter EL, Pittaluga S, et al. (2019) IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Alewine CC, Hassan R, Ahmad MI, et al. (2019) A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. Journal of Clinical Oncology. 37: 307-307 |